| Identification | Back Directory | [Name]
CAPADENOSON | [CAS]
544417-40-5 | [Synonyms]
CS-1666
BAY 68-4986
CAPADENOSON
Capadenoson, BAY 68-4986
2-Amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]-3,5-pyridinedicarbonitrile
3,5-Pyridinedicarbonitrile, 2-amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]-
2-amino-6-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile | [Molecular Formula]
C25H18ClN5O2S2 | [MDL Number]
MFCD09954113 | [MOL File]
544417-40-5.mol | [Molecular Weight]
520.035 |
| Chemical Properties | Back Directory | [Boiling point ]
787.9±70.0 °C(Predicted) | [density ]
1.51 | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [pka]
13.98±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Biological Activity]
Capadenoson (BAY 68-4986) is an adenosine receptor A1 (A1AR) partial agonist (GTPγS binding EC50/Emax = 0.1 nM/74% vs. 0.3 nM/100% with CCPA; human cortex membranes) th at exerts additional biased A2BAR agonism toward cAMP signal transduction (pEC50 = 8.94/cAMP6.20/Ca+26.12/pERK5.03/IP1)while exhibiting weak A2A & A3 potency. Capadenoson offers cardioprotection efficacy in an ischemia-reperfusion injury r at model in vivo (25/28% infarct size reduction with 0.1/0.3 mg/kg iv.) without the risk of a full atrioventricular (AV) block (isolated perfused r at heart rate = 100% up to 10 nM90% at ≥10 μM) seen with the full A1 agonist CCPA. | [target]
adenosine A1 receptor |
|
| Company Name: |
DKMbiochem.Co. Ltd Gold
|
| Tel: |
15901859516 |
| Website: |
http://www.dkmbiochem.com/ |
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|